In individuals with hepatorenal syndrome (HRS) compounded by alcoholic hepatitis (AH), treatment with the synthetic, long-acting vasopressin analogue terlipressin led to the achievement of verified HRS reversal, a subgroup analysis of the phase III CONFIRM trial has shown.
In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).
The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.
Nearly two in three participants in the placebo arm of nonalcoholic steatohepatitis (NASH) randomized clinical trials (RCTs) experience an adverse event (AE), while one in 10 have a serious AE, according to a pooled analysis of studies with NASH placebo.
An RNA interference therapy, ARO-HSD, is tolerable at ≤200-mg doses, suggests a phase I/II study. Short-term treatment with ARO-HSD results in decreases in hepatic HSD17β13 mRNA and protein expression, which is complemented by alanine aminotransferase reductions.